H igh-density lipoprotein (HDL) is thought to protect against atherosclerosis by extracting cholesterol from macrophages and delivering it to liver, from where it will be, in part, eliminated via bile and feces in a process usually known as reverse cholesterol transport (RCT). 1 Several studies have assessed overall RCT by measuring peripheral cholesterol synthesis, which in the steady state approximates centripetal cholesterol efflux to the liver. 2, 3 These studies have shown that overexpression or underexpression of apolipoprotein (apo) A-I does not perturb the RCT rate. However, they do not provide information on specific RCT from macrophages, a most important cholesterol-loaded cell in atherosclerotic lesions.
HDL are classified according to their content of the major apolipoproteins apoA-I and apoA-II. ApoA-I has a protective role against atherosclerosis, as demonstrated by the analysis of apoA-I transgenic mice. 4 Recently, tracing of reverse [ 3 H]cholesterol transport from macrophages to feces in apoA-I transgenic mice unambiguously demonstrated increased RCT in this atherogenic-resistant animal. 5 In contrast, the role of apoA-II is less understood. 6 -9 The overexpression of mouse apoA-II has been found to be pro-atherogenic. 10 Human apoA-II transgenic mice have also generally been found to display increased atherosclerosis susceptibility, but exclusively when fed an atherogenic diet [11] [12] [13] or when crossbred with apoE-deficient mice and fed a regular chow diet. 14 Mechanisms by which apoA-II expression may promote atherogenesis include impairing inhibition of the oxidative modification of apoB-containing lipoproteins and increasing inflammatory response of vascular cells. 15, 16 A further major pro-atherogenic mechanism of apoA-II expression may involve reduced RCT. 6, 9 Although the role of apoA-II on individual steps in the RCT pathway has been studied and reviewed in detail, 6 -9,13,17,18 little is known as to how apoA-II regulates the entire RCT rate in vivo. The present study tested the ability of human apoA-II to induce the macrophage-specific RCT pathway in vivo. Cholesterol-loaded P388D1 macrophage-like cells were used as the cell model because they express most of the cellular determinants of intracellular recycling of lipoprotein cholesterol 19 and exhibit apoptotic characteristics of vascular cells of atherosclerotic plaque. 20 
Methods

Mice and Diets
All animal procedures were in accordance with published recommendations. 21 Human apoA-II transgenic mice (line 11.1) were developed as previously described (Department of Medicine and Molecular and Cell Biology, Baylor College of Medicine, Houston, Tex). 22 Two-month-old C57BL/6 (control) and human apoA-II transgenic mice were maintained on a regular chow diet (Rodent Toxicology Diet; B&K Universal, UK) containing 0.02% cholesterol or an atherogenic diet (TD 88051; Harlan Teklad, Madison, Wis) containing 1.25% cholesterol, 15% fat, and 0.5% sodium cholate for 3 months. Male and female mice were used in equal proportions. All animal manipulations began at 12:00 PM with the mice fed ad libitum.
Lipid, Apolipoprotein, and Fecal Analyses
The methods used for plasma analyses have been described in detail elsewhere. 12, 14, 22 Lipids were extracted from 1 gram of feces with isopropyl alcohol-hexane; 14 the determination of cholesterol was performed using commercial kits as previously mentioned. 14 Fecal bile acids were extracted in ethanol and quantified using the 3␣-hydroxysteroid dehydrogenase method (Sigma Diagnostics, St. Louis, Mo). Intestinal cholesterol absorption was measured by a fecal dual-isotope ratio method. 23 12 LDL was then re-isolated by ultracentrifugation at 1.019Ͼ density Ͻ1.063 g/mL and acetylated by sequential addition of acetic anhydride. 24 The modified and labeled LDL was extensively dialyzed against saline before use. P388D1 mouse macrophages (ATTC; Manassas, Va) were cultured in 75-cm tissue culture plaques at 5 million cells per plaque and grown to 90% confluence in RPMI 1640 supplemented with 10% fetal bovine serum. Mouse macrophages were incubated for 48 hours in the presence of 100 g/mL of [ 3 H]cholesteryl oleate-labeled acetylated LDL (specific activity 9ϫ10 6 dpm/mg apoB) and RPMI 1640 supplemented with 10% lipoprotein-depleted serum. Cellular uptake of [ 3 H]cholesteryl oleate-labeled LDL resulted in the accumulation of large quantities of cholesteryl esters visible as free droplets in the cytoplasm of Oil red O-stained P388D1 mouse macrophages. These cells were washed, equilibrated, detached with cell scrapers, and resuspended in saline. 5 The distribution of [ 3 H]cholesterol between free cholesterol and cholesteryl ester was determined by thin-layer chromatography. 22 
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increased apoB-containing lipoproteins after being fed the atherogenic diet (Table) . The 11.1 transgenic mice fed the atherogenic diet had increased cholesterol levels in very-lowdensity lipoprotein and LDL (7.4 and 3.2 mmol/L, respectively) compared with those of the control group (2.2 and 0.8 mmol/L, respectively). Fecal cholesterol and bile acid output and intestinal cholesterol absorption did not differ between human apoA-II mice and control mice (Table) . No gender differences were found in any of the parameters studied.
Macrophage-Specific RCT in Chow-Fed Human ApoA-II Transgenic Mice
After intraperitoneal injection of [ 3 H]cholesterol-labeled macrophages, plasma [ 3 H]cholesterol levels from human apoA-II transgenic mice, both at 24 and 48 hours, were not significantly different from those of control mice ( Figure 1A ). Approximately 70% of radiolabeled [ 3 H]cholesterol was bound to HDL both in control and transgenic mice at 24 hours, decreasing significantly in transgenic mice at 48 hours (35% versus 55% in control mice; Figure 1A ). The major part of plasma labeled cholesterol was esterified in both groups of mice at 24 hours (66% and 67% in control and transgenic mice, respectively). At 48 hours, the plasma tracer of esterified cholesterol was 58% in transgenic mice and 63% in control mice, whereas in the liver it was, respectively, 10.7% and 17.4% of total labeled cholesterol. At the end of the experiment, [ 3 H]cholesterol in liver and feces was 1.3-fold and 6-fold higher in human apoA-II transgenic mice, respectively, than in control mice ( Figure 1B 
Macrophage-Specific RCT in Mice Fed the Atherogenic Diet
Plasma [
3 H]cholesterol levels, both at 24 and 48 hours, did not differ between the 2 groups of mice fed the atherogenic diet ( Figure 2A) . In contrast to findings in mice fed a chow diet, HDL-associated [ 3 H]cholesterol reached only Ϸ30% in both groups of mice at 24 hours. At this point of time, the major part of plasma labeled cholesterol was esterified in both control and transgenic mice (62% and 60%, respectively). At 48 hours after injection, the tracer corresponding to plasma esterified cholesterol was reduced in transgenic mice (51%) compared with control mice (65%). The percentage of liver labeled esterified cholesterol (compared with total cholesterol) was 51% and 42% in control mice and transgenic mice, respectively. The [
3 H]tracer detected in liver, fecal cholesterol, and bile acids of transgenic mice did not differ significantly from that of control mice ( Figure 2B ).
We repeated this experiment with transgenic mice of line 25.3 that expressed low concentrations of human apoA-II (14 mg/dL) after 6 weeks on the atherogenic diet. Again, the [ 3 H]cholesterol detected in liver showed no differences between transgenic and control mice (24 890Ϯ942 and 23 380Ϯ1054 dpm, respectively; nϭ5 in each group). No difference was found in [ 3 H] tracer of feces (3146Ϯ339 and 2557Ϯ297 dpm, respectively; nϭ5 in each group).
Discussion
Previous studies by our group indicated that the proatherogenic susceptibility to atherosclerosis in our human apoA-II transgenic mice fed an atherogenic diet might be caused by impaired RCT secondary to HDL deficiency. The latter was caused in part by decreased apoA-I levels, which, as a major cofactor of lecithin:cholesterol acyltransferase, induced a functional lecithin:cholesterol acyltransferase deficiency in these mice. 11, 17, 22 In contrast, the main conclusion of the present study is that the overexpression of human apoA-II effectively maintains RCT from macrophages to liver and feces.
It is noteworthy, however, that the human apoA-II overexpression in chow-fed mice enhanced RCT from macrophages to liver and feces, whereas the same RCT was Arterioscler Thromb Vasc Biol.
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unaltered in human apoA-II transgenic mice fed the atherogenic diet. Absolute radioactivity was similar in plasma of control and transgenic mice, demonstrating that the dietary and genotypic variations that strongly affected the concentration of different lipoprotein subclasses in the different mice groups were not critical, at least at the time points studied (24 and 48 hours). Given that in transgenic mice HDL concentrations are decreased, these results also indicate an increased relative radioactive label in HDL. We detected the presence of "lipid-free" human apoA-II in our transgenic mice by native gradient polyacrylamide gel electrophoresis (data not shown). This would be consistent with an efficient role of apoA-II-containing small HDL in inducing cholesterol efflux through ABCA1. 13 However, apoA-II transgenic mice present increased labeled lipid uptake from HDL by the liver when fed a chow diet. 25 Thus, increasing cholesterol efflux from macrophages and increasing delivery of cholesterol to the liver by HDL may explain our observations. However, several in vitro studies including our own experiments indicate that apoA-II exerts a negative effect on scavenger receptor type B-1 (SR-BI)-specific cholesteryl ester uptake. 18, 25 Although a recent study suggested that SR-BI is responsible for the bulk of liver HDL-selective cholesteryl ester uptake, 26 a minor SR-BI-independent mechanism for cholesterol-poor HDL has also been observed in mice. 26 Thus, it is possible that SR-BI-independent pathways [27] [28] [29] contribute to the enhanced uptake of HDL-derived cholesterol found in the liver of human apoA-II transgenic mice. Importantly, RCT from macrophages to feces is unaltered in human apoA-II transgenic mice fed the atherogenic diet despite an increased HDL-cholesteryl ester selective uptake by the liver (Ribas et al, unpublished data) and an increased atherosclerosis susceptibility. 11 A marked increase in [ 3 H]cholesterol bound to non-HDL particles was observed in the experiment performed with mice fed an atherogenic diet ( Figure 2 ). Considering that mice do not show cholesteryl ester transfer protein activity, the increase in [ 3 H]cholesterol bound to non-HDL particles may, in part, be caused by the action of plasma phospholipid transfer protein that exchanges cholesterol between HDL and apoB-containing lipoproteins, 30 especially in a situation in which the apoB-containing lipoprotein pool is increased compared with that of the chow diet (Table) . It is noteworthy that the ratio of liver-labeled cholesterol compared with that in plasma is markedly increased in mice fed an atherogenic diet compared with that obtained with a regular chow diet. In this context, it is also worth noting that liver-labeled cholesteryl esters were highly increased in mice fed the atherogenic diet versus chow-fed mice (Figures 1 and 2 ). This is concomitant with a dramatic increase in the content of liver cholesteryl ester (Ϸ25-and 30-times in control and transgenic mice, respectively), which contrasts with the mild increase in liver free cholesterol (between 1.5 and 2-fold in both types of mice). High-cholesterol, cholate-containing diets have been shown to induce acyl-coenzyme A (CoA):cholesterol acyl transferase 2 (ACAT2), the rate-limiting enzyme of liver cholesterol esterification. 31 Thus, an enhanced re-esterification of liver free [ 3 H]cholesterol by ACAT2 that is not completely matched by an increase in liver very-low-density lipoprotein secretion 32 may be a possible explanation for these observations as well as for the comparatively reduced excretion of [ 3 H]cholesterol in feces of mice fed the atherogenic diet with respect to their measured liver labeled cholesterol.
As a potential limitation of the study, it should be borne in mind that it remains to be established whether the P388D1 cholesterol-loaded cell behaves exactly as do endogenous murine macrophages with respect to RCT.
In conclusion, our studies show, for the first time to our knowledge, that human apoA-II effectively maintains RCT from macrophages to feces in vivo even in a situation of HDL deficiency. They may also indicate, together with the previous work of other groups, that apoA-II exerts at least part of its pro-atherogenic effect by counteracting antioxidant properties of HDL 15, 16 rather than by impairing macrophage-specific RCT.
